A Case of Development of Sarcoidosis During Tumor Necrosis Factor-alpha Antagonist Therapy
Journal of Rheumatic Diseases
;
: 41-45, 2011.
Artículo
en Coreano
| WPRIM
| ID: wpr-104648
ABSTRACT
Etanercept is a soluble receptor fusion protein that inhibits tumor necrosis factor-alpha(TNF-alpha). The receptor is used widely in the treatment of ankylosing spondylitis, rheumatoid arthritis, sarcoidosis and other indications. For sarcoidosis, it potentially suppresses granuloma formation with TNF-alpha blocking. On the other hand, recent studies have suggested that paradoxical sarcoidosis can be induced by TNF-alpha antagonists in some cases. A 42-year-old woman, who was treated with etanercept due to ankylosing spondylitis for 5 years, was admitted because of right suprahilar lymphadenopathy on chest radiography. Chest computed tomography revealed an enlargement of supraclavicular, paratracheal, mediastinal lymph nodes. She was diagnosed with sarcoidosis on the supraclavicular lymph node biopsy, which was non-caseating epithelioid cell granuloma and excluded from similar diseases. She was treated for sarcoidosis with prednisolone instead of etanercept.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Artritis Reumatoide
/
Sarcoidosis
/
Espondilitis Anquilosante
/
Tórax
/
Biopsia
/
Inmunoglobulina G
/
Prednisolona
/
Células Epitelioides
/
Factor de Necrosis Tumoral alfa
/
Receptores del Factor de Necrosis Tumoral
Límite:
Adulto
/
Femenino
/
Humanos
Idioma:
Coreano
Revista:
Journal of Rheumatic Diseases
Año:
2011
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS